Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Interest & Investment Income (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Interest & Investment Income data on record, last reported at $74379.0 in Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 143.58% year-over-year to $74379.0; the TTM value through Dec 2025 reached $236396.0, down 24.41%, while the annual FY2025 figure was $155882.0, 70.47% down from the prior year.
  • Interest & Investment Income reached $74379.0 in Q4 2025 per INM's latest filing, down from $93765.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $166760.0 in Q4 2023 and bottomed at $4222.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $80025.4, with a median of $73483.0 recorded in 2022.
  • Peak YoY movement for Interest & Investment Income: soared 2642.7% in 2022, then plummeted 86.36% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $4222.0 in 2021, then skyrocketed by 2642.7% to $115797.0 in 2022, then skyrocketed by 44.01% to $166760.0 in 2023, then crashed by 81.69% to $30536.0 in 2024, then surged by 143.58% to $74379.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $74379.0 in Q4 2025, $93765.0 in Q3 2025, and $51687.0 in Q2 2025.